Generated by Meeveem AI
"AI-enabled precision medicine for cardio-renal-metabolic disease"
MultiOmic Health develops precision therapeutics for age-related chronic diseases where genetics alone cannot explain why patients progress despite standard treatment. The company focuses on cardio-renal-metabolic conditions, a group of related diseases affecting over 2 billion patients worldwide and consuming $2 trillion in healthcare costs. Using deep longitudinal patient datasets, AI-enabled data science, and experimental biology expertise, MultiOmic Health identifies patient subpopulations with distinct molecular disease drivers. This precision platform enables targeted treatments with smaller, shorter clinical trials and higher success rates. The company is building a global patient registry capturing over 100,000 patients by 2028.
20
Team Members
2021
Founded
Biotechnology
Sector
Hybrid
Work Environment
A world where chronic cardio-renal-metabolic diseases are understood at the molecular level, enabling precise interventions that halt disease progression for every patient subpopulation rather than managing symptoms universally.
At MultiOmic Health, our mission is to become the preeminent central knowledge engine in cardio-renal-metabolic disease by identifying patient subpopulations and developing precision therapeutics for those who do not respond to standard care.